302 related articles for article (PubMed ID: 31335338)
1. Clinical trials in amyotrophic lateral sclerosis.
McDermott CJ
Curr Opin Neurol; 2019 Oct; 32(5):758-763. PubMed ID: 31335338
[TBL] [Abstract][Full Text] [Related]
2. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Jaiswal MK
Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
[TBL] [Abstract][Full Text] [Related]
3.
Palumbo JM; Hubble J; Apple S; Takei K; Tsuda K; Liu S; Zhang J; Agnese W
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Aug; 20(5-6):421-431. PubMed ID: 30982356
[No Abstract] [Full Text] [Related]
4. Edaravone for the treatment of amyotrophic lateral sclerosis.
Yoshino H
Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis.
Luo L; Song Z; Li X; Huiwang ; Zeng Y; Qinwang ; Meiqi ; He J
Neurol Sci; 2019 Feb; 40(2):235-241. PubMed ID: 30483992
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive
Benatar M; Wuu J; Andersen PM; Atassi N; David W; Cudkowicz M; Schoenfeld D
Neurology; 2018 Feb; 90(7):e565-e574. PubMed ID: 29367439
[TBL] [Abstract][Full Text] [Related]
7. Arimoclomol: a potential therapy under development for ALS.
Lanka V; Wieland S; Barber J; Cudkowicz M
Expert Opin Investig Drugs; 2009 Dec; 18(12):1907-18. PubMed ID: 19938902
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy.
Fortuna A; Gizzi M; Bello L; Martinelli I; Bertolin C; Pegoraro E; Corbetta M; Sorarù G;
J Neurol Sci; 2019 Sep; 404():47-51. PubMed ID: 31325668
[TBL] [Abstract][Full Text] [Related]
9. Early post-marketing experience with edaravone in an unselected group of patients with ALS.
Abraham A; Nefussy B; Fainmesser Y; Ebrahimi Y; Karni A; Drory VE
Amyotroph Lateral Scler Frontotemporal Degener; 2019 May; 20(3-4):260-263. PubMed ID: 30784320
[No Abstract] [Full Text] [Related]
10. Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.
Blasco H; Patin F; Andres CR; Corcia P; Gordon PH
Expert Opin Pharmacother; 2016 Aug; 17(12):1669-82. PubMed ID: 27356036
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
[TBL] [Abstract][Full Text] [Related]
12. [Edaravone: A New Treatment for ALS].
Yamashita T; Abe K
Brain Nerve; 2019 Nov; 71(11):1245-1251. PubMed ID: 31722310
[TBL] [Abstract][Full Text] [Related]
13. Disease-modifying treatment of amyotrophic lateral sclerosis.
Schultz J
Am J Manag Care; 2018 Aug; 24(15 Suppl):S327-S335. PubMed ID: 30207671
[TBL] [Abstract][Full Text] [Related]
14. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
Dash RP; Babu RJ; Srinivas NR
Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.
Johnson SA; Fang T; De Marchi F; Neel D; Van Weehaeghe D; Berry JD; Paganoni S
Drugs; 2022 Sep; 82(13):1367-1388. PubMed ID: 36121612
[TBL] [Abstract][Full Text] [Related]
16. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19).
Shefner J; Heiman-Patterson T; Pioro EP; Wiedau-Pazos M; Liu S; Zhang J; Agnese W; Apple S
Muscle Nerve; 2020 Feb; 61(2):218-221. PubMed ID: 31621933
[TBL] [Abstract][Full Text] [Related]
17. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis.
Phukan J
IDrugs; 2010 Jul; 13(7):482-96. PubMed ID: 20582873
[TBL] [Abstract][Full Text] [Related]
18. Edaravone May Prevent Ferroptosis in ALS.
Spasić S; Nikolić-Kokić A; Miletić S; Oreščanin-Dušić Z; Spasić MB; Blagojević D; Stević Z
Curr Drug Targets; 2020; 21(8):776-780. PubMed ID: 32077821
[TBL] [Abstract][Full Text] [Related]
19. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).
Bireley JD; Morren JA
Expert Opin Investig Drugs; 2023; 32(8):677-683. PubMed ID: 37642362
[TBL] [Abstract][Full Text] [Related]
20. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
Bhandari R; Kuhad A; Kuhad A
Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
